Cutaneous Stevens Johnson – Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients
- 18 January 2022
- journal article
- case report
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (5) , 1276-1282
Abstract
Introduction: New Immuno- Checkpoint inhibitors (ICIs) functioning as PD-1- PDL-1 blockers are nowadays used in a majority of anticancer treatments. Many immune- related Adverse Events (irAEs) are published daily; severe skin toxicities, Stevens Johnson/ Toxic Epidermal Necrolysis (SJS/TEN) are seldom reported. Case report: Herein, we present two interesting skin sever toxicity cases of lung cancer patients, undergoing PD-1- PDL-1 Immunotherapy. In both cases, a morbilliform rash with documented histological Toxic Epidermal Necrolysis Pattern /Stevens Johnson findings, was thoroughly studied. Management & Outcome: Both cases were therapeutically managed according to guidelines with different outcome. Discussion: Two focused cases of irAEs, is the rationale, to briefly review mechanisms of major toxicities caused by PD-1/PD-L1 blockade, and present all new data in their precise management. ICIs’ association with SJS/ TEN still remains unclear; underlying urgent need for further studies. It is important to alert physicians to promptly identify life threatening irAEs. Being familiar, provides management efficacy, safe resolve and encourage beneficial balanced cost effective treatments.Keywords
This publication has 21 references indexed in Scilit:
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapyScience, 2018
- How Does SCORTEN Score?Journal of Burn Care & Research, 2017
- Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaAnnals of Oncology, 2017
- Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 TherapyClinical Cancer Research, 2016
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- Acute Respiratory Failure in Patients With Toxic Epidermal NecrolysisCritical Care Medicine, 2014
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literatureAnnals of Allergy, Asthma & Immunology, 2005
- Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema MultiformeArchives of Dermatology, 1993
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981